Curebase is set to partner with neuroscience technology company Redenlab for the expansion of data capture capabilities in pharma clinical trials.
Making use of speech and language biometrics, Redenlab improves decision-making in clinical trials.
The user-friendly digital speech platform of Redenlab provides flexible, objective measurement, and communication ability analysis.
This can evaluate the efficacy of pharma treatments as tools to monitor patient health in medical clinics and academic research.
Redenlab CEO Dr Adam Vogel said: “Our cognitive-linguistic tests are valid, quick, and reliable, with demonstrated sensitivity to subtle disease or treatment-induced change.
“We service in-clinic, in-home, or virtual trials, with speech software and hardware solutions capable of meeting regulatory requirements for security and integrity of data in clinical trials.”
To add speech analytics to pharmaceutical clinical trials, Curebase can integrate with the platform of Redenlab, with built-in AWS and HIPPA compliance, where required.
Providing researchers with a comprehensive monitoring approach in trials, this analytical component will also add to the safety and well-being of patients at the time of the trials.
Curebase will collect crucial metrics in a decentralised study model by using these capabilities, where applicable, in pharma and neuro trials.
Curebase founder and CEO Tom Lemberg said: “Data quality is a huge component to DCTs, being able to offer specific analytics to our research studies levels up our data collection capabilities in our trials.
“By incorporating Redenlab’s technology into pharma studies where necessary, we are able to produce quality data points where they matter.”
Through these partnerships, sponsors will be able to gather comprehensive and relevant data metrics in accordance with regulatory requirements for necessary clinical trials.
Last month, Curebase and clinical research operating platform BEKHealth entered a partnership to expand patient access to decentralised clinical trials.